U lcerative colitis (UC) is a chronic inflammatory disease of the colon characterized by mucosal ulceration and affects more than 1 million in the United States and Europe. 1 In both clinical practice and trials setting, monitoring disease activity in patients with UC is based on clinical symptoms with an emphasis on altered bowel habits and rectal bleeding. Unfortunately, relying on subjective symptoms alone may lead to management errors. 2 Endoscopy remains the gold standard objective measure of disease activity assessment but is not ideal for repeat monitoring due to the invasive nature, high costs, and small but significant risk of associated complications. 3 As a result, surrogate biomarkers of inflammation, including fecal calprotectin (FC), have emerged as a somewhat reliable indirect measure of inflammation, but its suboptimal testing characteristics do not allow for it to replace endoscopy. 4, 5 A "treat-to-target" strategy has been used to optimize the management approach in patients with rheumatoid arthritis and has been a hot topic of inflammatory bowel disease (IBD) research. The Selecting Therapeutic Targets in Inflammatory Bowed Disease initiative involved expert consensus to identify treatment targets for IBD. 6 Mucosal healing (MH) defined as a Mayo score of 0 or 1 emerged as the highest ranked treatment target for UC. 7 A composite endpoint of resolution of clinical symptoms and MH will be the primary target not just in the clinical setting but in future registration trials for new drug targets. The importance of achieving MH is linked to the data demonstrating its association with more durable remission rates and decreased colectomy rates. [8] [9] [10] Although histological remission as a treatment target was not thought to be ready for prime time, there is currently a lot of interest in exploring this as a treatment goal, but more data are needed to determine if histological, in addition to clinical, activity alters prognosis. The persistence of active histological inflammation has been associated with an increased risk of relapse in comparison with normal activity. [11] [12] [13] Microscopic activity has also been associated with increased risk of recurrent hospitalizations, colectomy rates, and risk of colorectal neoplasia. [14] [15] [16] [17] If proven that histological remission improves short-term and long-term outcomes over and above that afforded by MH, then the search for a noninvasive biomarker that accurately predicts histology and not just endoscopic appearance becomes important. We aimed to evaluate the accuracy and clinical utility of FC levels to predict histological remission in patients with UC.
MATERIALS AND METHODS

Study Population
We retrospectively reviewed the charts of established pediatric and adult patients with UC managed between 2012 and 2016 at the Susan and Leonard Feinstein Inflammatory Bowel Disease Center, Mt. Sinai Hospital. Only those patients who had undergone a full colonoscopy because of disease flare or regular surveillance in combination with a fecal calprotectin (enzymelinked immunosorbent assay-based assay) collected within 6 weeks of the colonoscopy and negative infectious workup were eligible. The institutional review board at Mt. Sinai Hospital approved the study.
Data Collection
Chart reviews were completed from electronic medical records and data collection included date of diagnosis, disease duration in years, extent of disease, clinical/endoscopic/histological activity, complete blood count, C-reactive protein, and FC level.
Outcome and Disease Activity Definitions
Clinical Remission
Clinical disease activity was evaluated by patient-reported outcome measures (PRO2) consisting of rectal bleeding ¼ 0 and stool frequency #2, with remission determined as a score ¼ 0. 18 
Endoscopic Remission
To ensure consistent accuracy of inflammation and disease extent, all patients had undergone a full colonoscopy performed by IBD-specialized Gastroenterology physicians within the Department of Gastroenterology at Mt. Sinai Hospital. Disease extent was assessed based on the Montreal Classification divided into E1 (proctosigmoiditis), E2 (left-sided disease), and E3 (pancolitis). 19 Biopsies were obtained from un-inflamed and inflamed colonic mucosa. The endoscopic activity was assessed according to the Mayo endoscopic subscore (MES), and MH was defined by a Mayo score of grade 0. 7 
Histological Remission
We applied the Nancy histological scoring system, which uses a simple 3-descriptor scoring system. 20 We defined histological remission as a Nancy score of 0 or 1. Deep remission was defined as patients with a PRO2 score of 0 and MES subscore of 0. Deeper remission was defined as patients with a PRO2 score of 0, MES subscore of 0, and Nancy score of 0 or 1.
Statistical Analysis
All analyses were performed using IBM SPSS Statistics for Mac OS Version 21.0 (IBM Corp., Armonk, NY). FC levels were expressed in micrograms per gram, summarized as median with range, and compared within individual groups by Mann-Whitney U test and pairwise comparison. Pearson's correlation was used to estimate the association between FC levels and histological scores. Accuracy analysis included receiver operating characteristic (ROC) curve analysis with 95% confidence intervals and test characteristics to include sensitivity, specificity, and positive and negative predictive values. All tests were 2-sided and acceptable threshold for type 1 error was set at 0.05.
RESULTS
Demographics
During the study period, 68 patients with UC met the inclusion criteria and were analyzed ( Table 1) . The majority of patients were female (59%) with a median age of 26 years (range, 2-56 years) and median disease duration of 6.9 years (range, 1.0-26.4 years). Patients were predominantly nonsmokers (81%) and 46% had extensive disease location (E3). With respect to therapy, a majority of patients were maintained on mesalaminebased therapy (46%) or tumor necrosis factor inhibitors (21%). Forty-seven percent of patients had an elevated C-reactive protein (cutoff of 1 mg/L) at the time of endoscopy with a median level of A majority of patients were not in clinical remission based on PRO2 (66%). With respect to endoscopic activity, patients were relatively evenly distributed: 25% Mayo 0, 26.5% Mayo 1, 23.5% Mayo 2, and 25.5% Mayo 3. Histologically, 22% had a Nancy score of 0 or 1, 35% Nancy 2, and the remaining 43% a Nancy score of 3 or 4. Deep remission was achieved by 21% of patients and 15% deeper remission (Table 2 ).
Calprotectin and Disease Extent and Activity
Higher FC levels were associated with increasing extent of disease (E1 versus E3) (P , 0.06). There was, however, no significant difference when comparing levels of FC between E1 to E2 (259 versus 286 mg/g) and E2 to E3 (286 versus 621 mg/g). Patients in clinical remission (PRO2 ¼ 0) had significantly lower FC levels compared with those not in remission (50 versus 409 mg/g, P , 0.01) ( Table 2 ). Increasing FC levels were associated with increasing severity of endoscopic activity as defined by the MES (P , 0.001). Patients with complete MH (Mayo 0) showed lower FC levels compared with Mayo 1, 2, and 3 (40 versus 267, 429, and 857; P , 0.001).
FC level directly correlated with increasing histological inflammatory activity as determined by the Nancy score (r ¼ 0.573, P , 0.001). FC levels were significantly lower in patients with Nancy 0/1 compared with Nancy 2, 3, and 4 (359, 245, and 695, respectively; P , 0.001). A significant difference was not observed between a Nancy score of 0 and 1 (histological remission) (28.5 versus 40 mg/g; P , 0.5). Patients with Mayo 0/1 and Nancy score #1 (n ¼ 15) had significantly lower FC levels compared with those with standard definitions of MH (Mayo 0/1) and histological activity (Nancy $ 2, n ¼ 20) (31 versus 231; P , 0.001; Fig. 1 ).
ROC analysis revealed area under the curve of 0.92 (95% confidence interval, 0.86-0.99) for deep remission with a specificity of 87%, sensitivity 86%, positive predictive value 86%, and negative predictive value 87% for an FC cutoff ,60 mg/g (Fig.  2A) . With respect to deeper remission, ROC analysis revealed an area under the curve of 0.91 (95% confidence interval, 0.84-0.98) with a specificity of 90%, sensitivity 83%, positive predictive value 83%, and negative predictive value 98% with the same FC cutoff of ,60 mg/g (Fig. 2B) .
DISCUSSION
Objective measures of disease activity that are accurate, durable, and responsive to change are important treatment targets. To date, MH as defined endoscopically remains the gold standard upon which other measures, such as histology and biomarkers, are matched up against. Composite definitions of remission are being used in both the clinic and in the experimental settings, and surrogate markers that accurately reflect these varying degrees of remission are needed. In our study, we assessed the association of FC concentrations with clinical, endoscopic, and histological disease activity.
Based on the "treat-to-target" strategy, MH has been identified as primary treatment target; however, assessment typically involves frequent endoscopy, which is limited by high costs and associated complications. FC is often being used as a noninvasive alternative to endoscopy but its accuracy in diagnosing MH remains suboptimal. A small study reported that the accuracy of FC was improved upon when predicting histological activity at week 8 in infliximab-treated patients, 21 but more data are needed and ideal cut points to discriminate levels of healing merit exploration. 22, 23 We demonstrated that the calprotectin levels correlated with extent of disease and worsening disease activity as defined clinically, endoscopically, and histologically in patients with UC.
Additionally, we observed that despite having MH with a Mayo score of 0 or 1, patients with histological activity with a Nancy score $2 had significantly elevated FC levels. Kristensen et al 24 identified an optimal FC cutoff of 61 mg/g for a Mayo score of 0 but reported lower clinical performance of FC based on ROC analysis when including patients with both Mayo scores of 0 to 1. The authors speculated whether microscopic inflammation in normal-appearing mucosa could change FC levels. 24 Rosenberg et al 25 further demonstrated histological evidence in up to 30% of patients classified by endoscopy as a Mayo grade 0. The persistence of active histological inflammation has been implicated in the risk of relapse and recurrent hospitalizations and colorectal neoplasia. 11, 14, 17 These important outcomes call into question whether histological remission should be a treatment target in addition to MH. If histological healing were to be an important endpoint, it would be necessary to find the optimal cut point of calprotectin that most correlates with depth of remission. In a recent study, Theede et al 23 observed that an FC level below 171 mg/g predicted histological remission. Guardiola et al 22 demonstrated an FC cutoff of ,155 mg/g accurately predicted histological remission with an area under the curve of 0.754. Based on our study, we were able to identify an optimal FC cutoff level to predict histological remission in UC. With respect to both deep and deeper remission, we found that an optimal FC cutoff of #60 mg/g accurately predicted remission with a specificity/sensitivity of 87%/86% and 90%/83%, respectively. Based on this finding, we expected to have significantly low FC levels, especially in patients with deeper remission, as these patients demonstrate histological healing. Our findings are similar to FC cutoff levels that have been used to help differentiate patients from IBD and irritable bowel syndrome. Banerjee et al 26 demonstrated that an FC cutoff ,50 mg/g can accurately distinguish patients with IBS from IBD in the investigation for chronic diarrhea. Such findings are consistent with other larger studies. 27, 28 Because IBS does not necessarily demonstrate any significant histological inflammation, we believe that patients in histological remission should correlate with similar FC levels. Our study is limited by the small sample size but our strict inclusion criteria limited those patients eligible for analysis. Additionally, the lack of central reading for both endoscopic and histological scoring may be viewed as a limitation but investigators very experienced with the Mayo scoring system performed all scopes and IBD pathologists read all pathology slides. The Nancy score has not been extensively studied and our findings will need to be validated in a separate cohort.
In summary, our study demonstrates that FC is useful in predicting depth of remission in patients with UC. Further prospective studies are needed to validate optimal FC cutoff levels and formally explore its role as a valuable noninvasive treatment target.
